Compare Dollar Tree, Inc. (DLTR) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Nuwellis Inc — how do they compare? Dollar Tree, Inc. trades at $118.89 (market cap $22.26B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Dollar Tree, Inc. is far larger — about 10118.2× Nuwellis Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Nuwellis Inc for 26 Days on average.
| DLTR | NUWE | |
|---|---|---|
Market Cap | $22.26B | $2.20M |
Volume | 2,317,428 | 121,544 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $146.65 |
52-Week Low | $86.80 | $0.68 |
Typical Hold Time | 58 Days | 26 Days |
Enterprise Value | $28.87B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $117.42, up 0.96% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.54. Recent news highlights strategic initiatives and store expansions supporting growth, though margin risks from tariffs and reinvestment remain a focus.
The outlook is positive with a consensus price target of $139.33, implying 18.7% upside, but investors face risks from volatile margins, high debt levels, and competitive pressures. Earnings improvement and institutional buying provide support, yet the stock's recent decline of 17.9% over the past month underscores near-term challenges.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
